drugset / Trial / NCT04435717
Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)
RandomizedSingle-groupOpen-labelTreatment
Summary
unicenter, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19.
Timeline
- Start
- 2020-05-04
- Primary completion
- 2020-11-04
- Completion
- 2021-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |